Valuation Watch: As Biopharma IPOs Return, Does Value?
This article was originally published in Start Up
Executive Summary
At least a dozen companies that roughly fit the description of a venture-backed, R&D focused biotech or small pharmaceutical company have gone public since mid-2009. Here we look at how valuations stack up compared to M&A and previous IPO windows.